Phenylene alkyne matrix metalloproteinase inhibitors

A compound of Formula II

• or a pharmaceutically acceptable salt thereof, or a tautomer thereof, wherein:
• G1 is
• (CH2)maryl,
• (CH2)msubstituted aryl,
• (CH2)mheteroaryl, or
• (CH2)msubstituted heteroaryl,
• wherein
• E is O;
• A is NR1R2;
• R1 is hydrogen;
• R2 is
• (CH2)naryl,
• (CH2)nsubstituted aryl,
• (CH2)nheteroaryl, or
• (CH2)nsubstituted heteroaryl;
• m is 1;
• n is 1;
• R5, R6, and R7 independently are hydrogen, halo, hydroxy, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, NO2, CN, CF3, or NR9R10, wherein R9 and R10 independently are hydrogen, C1-C6 alkyl, C3-C7 cycloalkyl, phenyl, or benzyl, or R9 and R10 are taken together with the nitrogen atom to which they are attached to complete a 3- to 7-membered ring having carbon atoms, the nitrogen atom bearing R9 and R10, and 0 or 1 heteroatoms selected from N(H), N(CH3), O, and S;
• wherein each aryl independently is phenyl or naphthyl;
• wherein each substituted aryl independently is phenyl or naphthyl substituted with from 1 to 3 substituents independently selected from selected from phenyl, cyano, CO2H, SO2NH2, CH3SO2, CH3S, alkyl, alkoxy, thio, thioalkyl, heteroaryl, heterocyclyl, halo, hydroxy, —COOR9, trifluoromethyl, nitro, amino of the formula —NR1R2, and T(CH2)mQR3 or T(CH2)mCO2R3, wherein m is 1 to 6;
• T is O, S, NR3, N(O)R3, NR1R2Y, or CR1R2, Q is O, S, NR3, N(O)R3, or NR1R2Y, wherein R1 and R2 are described above, and R9 is alkyl or substituted alkyl;
• wherein each heteroaryl independently is selected from pyridyl, benzothienyl, furanyl, indolyl, benzotriazolyl, indazolyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, [1,2,3]triazolyl, [1,2,4]triazolyl, benzofuranyl, thienyl, benzisoxazolyl, benzisothiazolyl, isoxazolyl, isothiazolyl, and oxazolyl;
• wherein each substituted heteroaryl is heteroaryl as defined above substituted with 1 or 2 substituents independently selected from alkyl, thio, and alkoxy.